Founded in early 2018, Uvax Bio, a spin-off vaccine company from Scripps Research, La Jolla, CA, employs patented single-component self-assembling protein nanoparticle (1c-SApNP) platform technology developed by Professor Jiang Zhu of Scripps Research to develop and commercialize B-cell focused, rapid antibody-eliciting, preventive vaccines for the most challenging diseases around the world.

Our 1c-SApNP technology streamlines vaccine development and has delivered promising vaccine candidates to address global health challenges such as HIV, RSV/hMPV, PIV1-5, Ebola/Marburg, Lassa, coronaviruses including SARS-CoV, MERS-CoV and SARS-CoV-2, HCV, ZIKV/DENV, and non-viral diseases such as Malaria and Tuberculosis.

Biotechnology

Life Sciences

Therapeutics

Uvax Bio

Ji Li

Deven Sandhu

Pedro Garbes

Ke Li

Kevin O'neill

Jiang Zhu

The Research and Development team at Uvax Bio focuses on advancing the company's innovative 1c-SApNP vaccine platform. They conduct fundamental and applied research to design and optimize vaccine candidates aimed at eliciting robust B-cell responses against various infectious diseases. This team collaborates closely with other departments to streamline the vaccine development process, ensuring that promising candidates progress effectively from conceptualization through clinical trials.

Research and Development

Leadership Team

Research and Development

About

Team members

Other teams at Uvax Bio

Leadership Team